<PAGE>
This document consists
of 5 pages, of which
this page is number 1.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): April 9, 1998
BIOSOURCE INTERNATIONAL, INC.
(Exact name of registrant as specified in its charter)
Delaware 000-21930 77-0340829
- -------------------- --------- -----------------
(State or other jurisdiction of (Commission (I.R.S. Employer
incorporation or organization) File Number) Identification No.)
820 Flynn Road Camarillo, California 93012
- ------------------------------------- -----
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (805) 987-0086
<PAGE>
This document consists
of 5 pages, of which
this page is number 2.
ITEM 5. OTHER EVENTS
Reference is made to the press releases of Registrant, issued on April 9, 1998
which contain information meeting the requirements of this Item 5, and which are
incorporated herein by this reference. Copies of the press releases are attached
to this Form 8-K as Exhibit "A".
<PAGE>
This document consists
of 5 pages, of which
this page is number 3.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
April 15, 1998 BIOSOURCE INTERNATIONAL, INC.
By: /s/ James H. Chamberlain
--------------------------------
James H. Chamberlain, President,
and Chief Executive Officer
<PAGE>
EXHIBIT A
[LETTERHEAD OF BIOSOURCE INTERNATIONAL, INC.]
COMPANY CONTACTS: Anna M. Anderson, Chief Financial Officer
Aspasia Alexander, Investor Relations
805/987-0086, or <http:/www.biosource.com>
PRESS CONTACT: FS Communications
Matthew Schmidt
650/691-1488
BIOSOURCE INTERNATIONAL, INC. NAMES NEW CFO;
ALSO APPOINTS NEW EUROPEAN GENERAL MANAGER
Amgen Executive Named As Chief Financial Officer To Replace Anna M. Anderson,
Company Also Names New General Manager In Europe and Appoints Sales V.P.
Camarillo, Calif. -- April 9, 1998 -- BioSource International, Inc.
(Nasdaq: BIOI) today announced that Anna M. Anderson, chief financial officer
and executive vice president, is leaving the company for personal reasons. The
Company also announced that Larry A. May will join BioSource International, Inc.
as executive vice president and chief financial officer on June 1, 1998.
Mr. May is currently vice president and treasurer of Amgen, Inc. Ms.
Anderson will serve as a consultant to the Company after her departure on June
30, 1998.
"During her seven-year tenure at BioSource and its predecessor company,
Anna Anderson made enormous contributions to our growth and success. We all are
sad that she is leaving, but understand her wish to spend more time with her
family," said James H. Chamberlain, chairman, president and chief executive
officer of BioSource International. "We are also very fortunate to have her role
filled by Larry May, who has been with Amgen throughout its 15-year growth from
start-up to the world's largest biotechnology company."
During his 15-year tenure at Amgen, Inc., Mr. May served as corporate
controller, chief accounting officer and then treasurer. He assisted in building
the company into a global corporation with annual revenue surpassing $2.2
billion, and was directly involved in the negotiation of business partnerships
and strategic alliances, acquisition and implementation of computer and
communications systems, and staff development. Mr. May began his professional
career with Arthur Andersen & Co. in 1971.
more...
<PAGE>
BIOSOURCE NAMES NEW CFO/2-2-2
BioSource also announced that Jozef ("Jeff") Vangenechten, Ph.D. has been
named general manager of BioSource Europe, S.A., effective on April 20, 1998.
Edward Sapp, Jr., presently the general manager of the European subsidiary, will
return to the United States and serve as vice president of sales for BioSource
International, Inc.
"The appointment of Jeff Vangenechten as General Manager in Europe, which
allows us to bring Ed Sapp to the U.S. to run sales operations, is also an
exciting move forward for BioSource," said Chamberlain. "Jeff is an accomplished
scientist and manager, with more than two decades of experience in physiology,
radiobiology and business consulting. Ed has done a great job running BioSource
Europe since the company was established and now we can bring his skills to bear
across the Company's sales operations."
Mr. Vangenechten, a native of Belgium, spent the last decade as a business
manager and consultant with SGS (Societe Generale de surveillance), an
international group of companies working in environmental and life sciences
fields that works with both private industry and government institutions
throughout Europe. He received his Ph.D. in Physiology in 1980, and was employed
as a researcher in the Department of Radiobiology of the Belgian Nuclear Energy
Research Centre until 1988.
Mr. Sapp was named General Manager of BioSource Europe, S.A. in June 1996.
In a career spanning more than 30 years, he has held sales and management
positions with Amersham Corporation, Lancer Diagnostic, Inc., ASOMA and other
companies engaged in biomedical supply and medical diagnostics businesses.
BioSource International, Inc. is a Camarillo, Calif., based supplier of
immunological reagents and test kits used in biomedical research. The Company
offers more than 1,700 products, including recombinant proteins, monoclonal
antibodies and ELISA assay kits to a variety of antigens, and custom DNA
segments (oligonucleotides). For the year ended December 31, 1997, the Company
reported net income of $3,186,363 on revenue of $20,571,835.
This News Release may contain forward-looking statements that involve risks
and uncertainties, as described from time to time in reports filed by BioSource
with the Securities and Exchange Commission, including its most recently filed
Annual Report on Form 10-K.
###
